Saturday, February 23, 2019

Biotech IPO For The Week Ahead

Kaleido Biosciences is a clinical-stage healthcare company developing microbiome metabolic therapies or MMTs, which are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ's existing microbes.

from RTT - Biotech https://ift.tt/2Ivtup3
via IFTTT

No comments:

Post a Comment